The ongoing evolution of antibody-based treatments for Ebola virus infection

Emelissa J. Mendoza, Trina Racine, Gary P. Kobinger

Research output: Contribution to journalArticlepeer-review

18 Scopus citations


The 2014-2016 Ebola virus outbreak in West Africa was the deadliest in history, prompting the evaluation of various drug candidates, including antibody-based therapeutics for the treatment of Ebola hemorrhagic fever (EHF). Prior to 2014, only convalescent blood products from EHF survivors had been administered to newly infected individuals as a form of treatment. However, during the recent outbreak, monoclonal antibody cocktails such as ZMapp, ZMAb and MB-003 were either tested in a human clinical safety and efficacy trial or provided to some based on compassionate grounds. This review aims to discuss the evolution of antibody-based treatments for EHF, their clinical trial efficacy and the development of new antibody-based therapies currently advancing in preclinical testing.

Original languageEnglish (US)
Pages (from-to)435-450
Number of pages16
Issue number5
StatePublished - Mar 2017
Externally publishedYes


  • clinical trials
  • convalescent plasma
  • Ebola virus
  • monoclonal antibodies
  • outbreak
  • pan-ebolavirus
  • pan-filovirus
  • therapeutics

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Oncology


Dive into the research topics of 'The ongoing evolution of antibody-based treatments for Ebola virus infection'. Together they form a unique fingerprint.

Cite this